Optimize Hepatitis C Treatment

Chronic Hepatitis C virus (HCV) affects an estimated 3.5 million Americans, making it the most common blood-borne disease in the U.S. Left untreated, HCV can result in chronic liver disease, liver failure, liver cancer or even death. New drugs can cure HCV in upwards of 90 percent of patients, but the treatment comes with a huge price tag: the initial launch price was nearly $100,000 for a 12-week course. Recognizing these challenges, clinical and health plan leaders at Geisinger Health Plan created a robust protocol for the diagnosis and treatment of HCV.

Download Case Study


Learn how ACHP Plans are Promoting Evidence-Based Care

This creation of some site content was partially funded through a Patient Centered Outcomes Research Institute® (PCORI®) Eugene Washington PCORI Engagement Award (4109-ACHPF).

The views presented in this content are solely the responsibility of ACHP and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute® (PCORI®), its Board of Governors or Methodology Committee.

Press Contact

All media inquiries should be directed to:

Mat Gulick
Director, Communications
Making Health Care Better

ACHP is the voice of a unique approach in health care today, one that puts the patient at the center with plans and clinical teams collaborating to improve health outcomes and reduce costs. Our advocacy focuses on providing policymakers with tested solutions, rooted in a model that is proven to deliver better value for patients, employers and taxpayers.

icon-arrow
client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo
icon-arrow

Stay Connected